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cAMP-Binding Protein Epac Induces
Cardiomyocyte Hypertrophy
Eric Morel, Andrea Marcantoni, Monique Gastineau, Rikke Birkedal, Francesca Rochais, Anne Garnier,
Anne-Marie Lompre´, Gre´goire Vandecasteele, Frank Lezoualc’h
Abstract—cAMP is one of the most important second messenger in the heart. The discovery of Epac as a guanine exchange
factor (GEF), which is directly activated by cAMP, raises the question of the role of this protein in cardiac cells. Here
we show that Epac activation leads to morphological changes and induces expression of cardiac hypertrophic markers.
This process is associated with a Ca2-dependent activation of the small GTPase, Rac. In addition, we found that Epac
activates a prohypertrophic signaling pathway, which involves the Ca2 sensitive phosphatase, calcineurin, and its
primary downstream effector, NFAT. Rac is involved in Epac-induced NFAT dependent cardiomyocyte hypertrophy.
Blockade of either calcineurin or Rac activity blunts the hypertrophic response elicited by Epac indicating these
signaling molecules coordinately regulate cardiac gene expression and cellular growth. Our results thus open new
insights into the signaling pathways by which cAMP may mediate its biological effects and identify Epac as a new
positive regulator of cardiac growth. (Circ Res. 2005;97:0-0.)
Key Words:cAMP  guanine nucleotide exchange factor  small G protein  transcription factor
In the heart, cyclic adenosine 3,5-monophosphate (cAMP)regulates many physiological processes such as contractil-
ity and relaxation. Classically, these effects are attributed to
activation of hyperpolarization-activated cyclic nucleotide-
gated channels and protein kinase A (PKA) by cAMP.1 The
recent discovery of Epac as proteins which are directly
activated by cAMP has broken the dogma surrounding cAMP
and PKA.2–4 Epac proteins are guanine nucleotide exchange
factors (GEFs) that bind cAMP with affinities similar to that
of the regulatory subunit of PKA.2,3 They have been shown to
function as GEFs for the Ras-like small GTPases Rap1 and
Rap2 and are directly activated by cAMP in a PKA indepen-
dent manner.4 There are two isoforms of Epac, Epac 1 and
Epac 2 both consisting of a regulatory and a catalytic
region.2,3 Epac 2 has an additional cAMP binding domain that
is dispensable for cAMP-induced Rap activation.5 After
cAMP binding, Epac catalyzes the exchange of GDP for GTP
on the small GTPases Rap, allowing interaction with their
target effectors.6 Recent studies indicate that Epac is involved
in cell adhesion,7,8 neurite extension,9 and regulates insulin
secretion and the amyloid precursor protein processing.10,11
To date the role of Epac in the heart is unknown.
Among the superfamily of small G proteins, the Rho
family, which includes Rho, Rac, and Cdc42, has attracted
much interest for they have been shown to play key roles in
the generation of cytoskeletal structures.12 Indeed, Rho is
important for the formation of stress fibers and focal adhe-
sions in fibroblasts, whereas Rac and Cdc42 are involved in
the regulation of more dynamic structures such as membrane
ruffles, lamellipodia and filopodia.12 Several studies have
pointed out the role of Rho proteins in the development of
cardiomyocyte hypertrophy.13 For instance, two potent hy-
pertrophic stimuli, endothelin 1 (ET-1) and phenylephrine
(PE), induce rapid activation of endogenous Rac in neonatal
cardiomyocytes.14 In addition, adenoviral infection of cardio-
myocytes with a constitutive active form of Rac (RacG12V)
increases protein synthesis and promotes morphological
changes associated with myocyte hypertrophy.15 In vivo
evidence for the role of Rho proteins in cardiac hypertrophy
came from transgenic mice specifically expressing RacG12V in
the heart. These mice develop a dilated cardiomyopathy
associated with deregulation of cardiomyocyte focal adhe-
sions.16 These data suggest that Rho proteins, especially Rac
control hypertrophic response and are likely to be involved in
cardiac remodeling, and the pathogenesis of cardiomyopathy
characterized by cellular enlargement.
Recently, we have provided experimental evidence that
Epac stimulates the activity of the small GTPase, Rac, in a
cAMP-dependent but PKA-independent manner in neuronal
cells.11 These observations combined with the high expres-
sion of Epac in the heart2,3 prompted us to focus our research
on the potential role of Epac in cardiomyocyte hypertrophy.
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Here we found that Epac stimulates the activity of the small
GTPase, Rac, and increases the expression of hypertrophic
gene markers in primary cardiac myocytes. Furthermore, we
show that Epac induces cardiomyocyte hypertrophy. This
process is associated with the activation of Rac and the
calcineurin/NFAT signaling pathway, which coordinately
regulates cell growth and gene expression. Altogether, these
findings identify the cAMP-binding protein, Epac, as a new
positive regulator of cardiac growth.
Materials and Methods
Adenoviral Infection
Bicistronic adenoviruses (Ad5) bearing either EpacWT or
EpaccAMP under the control of a cytomegalovirus promoter and
green fluorescent protein (GFP) under internal ribosomal entry site
control were constructed and amplified at the Genethon Center of
Evry (France). Adenoviruses encoding VIVIT, a selective peptide
inhibitor of calcineurin-mediated NFAT activation, and Rac were
provided by Drs S. Kraner and C. Norris (University of Kentucky)
and T. Finkel (Cardiology Branch, National Heart, NIH, Bethesda,
Md), respectively. One day after plating, cardiomyocytes were
incubated for 2 hours with recombinant adenoviruses. After removal
of the virus suspension, cells were replaced in maintenance medium
for 2 days and then stimulated with the different drugs. Viruses were
used at a multiplicity of infection (MOI) of 100.
Plasmid Constructs and Transfection
The plasmid constructs were generously provided by the following:
the rat ANF promoter fused to the luciferase reporter gene (ANF-
Luc) by Dr K. Knowlton, Luciferase reporter genes linked to
promoters for skeletal muscle -actin (SkM--actin-Luc) and serum
response element-regulated c-fos (c-fos-SRE-Luc) by Dr M. D.
Schneider, Epac1 plasmid constructs by Drs J. Bos and X. Cheng.
The luciferase reporter plasmid driven by four NFAT consensus
binding sites (NFAT-Luc) was obtained from Stratagene. Transient
transfection experiments were performed with Lipofectamine 2000
(Invitrogen Life Technologies, France) in optimum medium in the
presence of 1 g of the various plasmid constructs according to the
manufacturers’ instructions.
Rac Activation Assay
Rac pull-down experiments were performed using a GST fusion
protein containing the Cdc42/Rac Interactive Binding Domain
(CRIB) of p21-activated kinase (PAK) exactly as previously
described.11
Statistical Analysis
Results are expressed as meansSEM. Differences between groups
have been analyzed by one-way ANOVA followed by unpaired
Student t test. Differences were considered significant at P0.05,
P0.01, and P0.001.
For a description of other methods, see the expanded Materials
and Methods, available online at http://circres.ahajournals.org.
Results
Epac Activates the Small G Protein Rac
in Cardiomyocytes
Activation of endogenous Epac with a selective activator of
this GEF, 8-pCPT-2-O-Me-cAMP (8-CPT), which does not
activate PKA17 increased Rac activation in rat cardiac myo-
cytes (Figure 1). Similarly, infection of cardiomyocytes with
an adenovirus encoding Epac1WT (Ad.EpacWT) significantly
enhanced Rac GTP-loading compared with control cells
infected with GFP (Figure 1). Rac activation was further
increased when cells infected with Ad.EpacWT were treated
with 8-CPT (Figure 1). An adenovirus bearing a constitutive
activated form of Epac1 (Ad.Epac-cAMP)2 also induced
Rac activation (Figure 1). Altogether, these results demon-
strate that recombinant and native Epac increase the amount
of Rac-GTP in cardiomyocytes.
Figure 1. Epac activates the small G
protein Rac in primary ventricular cardio-
myocytes. Cardiomyocytes were infected
with either Ad.GFP as a control or with
Ad.EpacWT or Ad.Epac-cAMP as
described in Materials and Methods.
Two days after infection, cells were
treated or not for 10 minutes with the
selective activator of Epac, 8-CPT (106
mol/L). Amounts of Rac-GTP were deter-
mined by pull-down experiments. A con-
trol for total Rac expression (total
lysates) is shown. The upper panel
shows a typical immunoblot. Expression
of recombinant proteins was determined
by Western blot using an anti-HA anti-
body. The lower panel shows
meansSEM of 3 independent experi-
ments. Results are expressed as fold
activation of control cells. *P0.05,
**P0.01 compared with control.
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Epac Increases the Expression of Hypertrophy
Gene Markers
As Rac has been found to be involved in cardiac myocyte
hypertrophy,15,16 we next tested the potential involvement of
Epac in this process. Re-expression of embryonic genes and
transient activation of immediate early genes are frequently
used indexes of myocyte hypertrophy.18 The ability of Epac
to stimulate gene expression was determined using luciferase
(Luc) constructs under the control of promoters for ANF,
SkM -actin, and the c-fos-SRE. Figure 2A shows a three-
fold activation of the ANF-Luc reporter gene in neonatal
cardiomyocytes stimulated with 8-CPT compared with con-
trol cells. Transient transfection of EpacWT or Epac-cAMP
increased the basal level of ANF-Luc activity (Figure 2A).
The effect of EpacWT on ANF-Luc activity was further
increased by the application of 8-CPT (Figure 2A). RacG12V
mimicked the effect of Epac on ANF-Luc activity (Figure
2A). Next, to analyze the effect of Epac on ANF mRNA
content in cardiac myocytes, we used Ad.EpacWT to maxi-
mize the expression of this GEF in primary cardiomyocyte.
Consistent with the effect of Epac on ANF-Luc reporter gene,
endogenous expression of ANF mRNA was significantly
increased in cardiomyocytes infected with Ad.EpacWT and
stimulated or not with 8-CPT, as compared with control cells
(Figure 2B). Similar results were obtained with an adenovirus
expressing RacG12V (Ad.RacG12V) (Figure 2B). In addition,
when cotransfection experiments were performed with SkM-
-actin-Luc or c-fos-SRE-Luc, 8-CPT, EpacWT, Epac-
cAMP, or RacG12V significantly increased Luc activity com-
pared with control cells (Figure 2C and 2D). The effect of
EpacWT on Luc activity was further increased by the applica-
tion of 8-CPT (Figure 2C and 2D).
Epac Increases Cardiomyocyte Size and
Sarcomeric Organization
Further studies were undertaken to determine the effects of
Epac on other features of the hypertrophic program such as
cell size and sarcomeric organization. Cardiomyocyte treat-
ment with Ad.GFP and 8-CPT as well as infection of
cardiomyocytes with Ad.EpacWT induced an apparent increase
of the F-actin meshwork and a heavily striated appearance,
reflecting the organization of this F-actin cytoskeleton into
sarcomeric structures, as compared with cardiomyocytes
infected with Ad.GFP alone (Figure 3A). Cells overexpress-
ing Epac were hypertrophied and were not contaminated by
fibroblast as shown by the -actinin staining in supplemen-
tary Figure I. In addition, the effects of Epac on sarcomeric
organization were comparable to Ad.Epac-cAMP (data not
shown) and PE (Figure 3A), a well-known inducer of cardiac
hypertrophy.
Next, we measured the effect of Epac on cell surface area.
Activation of endogenous Epac with 8-CPT produced a
two-fold increase in cell surface area when compared with
cells infected with control Ad.GFP (Figure 3B). Identical
results were obtained when cardiomyocytes were infected
with Ad.EpacWT (Figure 3B), Ad.Epac-cAMP (data not
shown), or Ad.GFP and treated with PE (Figure 3B). The
effect of Ad.EpacWT on cell surface area was not further
increased in the presence of 8-CPT suggesting that basal
intracellular cAMP was sufficient to activate recombinant
Epac to induce its maximal effect on protein synthesis (Figure
3B). Finally, the effect of Epac on protein synthesis was
analyzed by measurement of [3H]-leucine incorporation into
cardiac myocytes. Expression of this cAMP-GEF resulted in
an increase in [3H]-leucine uptake into cardiomyocytes (Fig-
ure 3C). Similarly, cell treatment with 8-CPT or the gold
standard, PE resulted in an approximately two-fold increase
in protein synthesis (Figure 3C). Altogether, these results
show that Epac activation confers to primary cardiomyocytes
all the features of the hypertrophic phenotype.
Intracellular Ca2 Is Involved in Epac-Dependent
Rac Activation
Alterations in intracellular Ca2 handling progressively exac-
erbate a hypertrophic or cardiomyopathic phenotype, in part
Figure 2. Epac stimulates a hypertrophic
pattern of gene expression. A, C, and D,
Neonatal cardiomycoytes were trans-
fected with ANF-Luc, SkM--actin-Luc
or c-fos-SRE-Luc and EpacWT, Epac-
cAMP, RacG12V, or the empty vector
(mock) as control and treated or not with
8-CPT (106 mol/L). Two days after
transfection, cells were assayed for Luc
activity. Results are expressed as per-
centage activation of control. Results are
meansSEM from 3 independent experi-
ments performed in triplicates. B, Epac
induces expression of ANF mRNA. Car-
diomyocytes were infected with Ad.E-
pacWT, Ad.RacG12V, or Ad.GFF (control)
and stimulated or not with 8-CPT (10-6
mol/L) for 2 days. ANF mRNA expression
was determined by quantitative PCR.
Values are expressed relative to the
ANF/GCB ratio and results were normal-
ized to control for each experiment.
Results are presented as the
meanSEM of 3 independent experi-
ments performed in duplicates. *P0.05,
**P0.01, ***P0.001 compared with
control.
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through sustained activation of Ca2-sensitive signal trans-
duction pathways.19 Given the involvement of Epac in cardiac
hypertrophy, we examined whether its activation could affect
intracellular Ca2 concentration ([Ca2]i) in neonatal myo-
cytes (Figure 4). At physiological external [Ca2], cardiac
myocytes exhibited spontaneous Ca2 transients with a low
frequency (0.1200.015 Hz, n20) (Figure 4A). Application
of the Epac agonist 8-CPT triggered a dramatic increase in the
frequency of these Ca2 oscillations (0.510.04 Hz, n7)
without changing the amplitude of the spikes. This effect was
also observed at 100 nM 8-CPT (0.400.05 Hz, n13, data
not shown).
Because Epac induced Rac activation, we examined the
dependence of Rac activation on Ca2 signaling. Treatment of
cardiac myocytes with the Ca2 ionophore ionomycin as well
as an inhibitor of the Ca2-ATPase, thapsigargin increased
Rac activation in a time dependent manner (Figure 4B and
4C). The effect of ionomycin and thapsigargin on Rac
activation was as potent as the positive control, PE (Figure 4B
and 4C). Pretreatment with BAPTA-AM, an intracellular
Ca2 chelator, attenuated Epac-induced Rac activation (Fig-
ure 4D). From these results we conclude that elevation of
intracellular [Ca2]i after Epac activation is sufficient to
activate Rac.
Figure 3. Epac induces cardiomyocytes
hypertrophy. A, Fluorescent microscopic
analyses of the effects of Epac on sarco-
meric organization. Morphology of repre-
sentative myocytes 48 hours after infec-
tion with Ad.GFP as a control, or
Ad.EpacWT is shown. The Epac selective
activator, 8-CPT was used at 106 mol/L
for 2 days in cells infected with Ad.GFP.
Positive control cells were infected with
Ad.GFP and treated with PE (105 mol/L)
for 2 days. Actin filaments were visual-
ized by using Rhodamin-conjugated
phalloidin. B, Photographic images of
cells treated as above were digitized.
The areas (106 m2) of 30 to 50 individu-
alized cells per condition from 2 to 3
independent experiments were deter-
mined by computer-assisted planimetry.
Values show the meansSEM. C,
[3H]-leucine incorporation. Cardiomyo-
cytes were treated as in (A) and total
radioactivity of incorporated [3H]-leucine
into proteins was determined by scintilla-
tion counting. The figure shows the
meanSEM of data for 3 experiments
performed in duplicate. *P0.05,
**P0.01, ***P0.001 compared with
control Ad.GFP.
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Epac Activates the Hypertrophic
Calcineurin/NFAT Signaling Pathways
One prominent Ca2-dependent pathway that plays a crucial
role in cardiomyocyte hypertrophy involves the phosphatase
calcineurin.20 Activation of calcineurin by Ca2 results in the
dephosphorylation and nuclear translocation of cytoplasmic
NFAT transcription factors, which then upregulate transcrip-
tion of hypertrophic genes. To test whether endogenous Epac
may activate the hypertrophic calcineurin NFAT signaling
pathway, cardiomyocytes were transfected with NFAT-Luc
and treated or not with 8-CPT (Figure 5A). 8-CPT signifi-
cantly increased NFAT transcriptional activity as compared
with control cells (Figure 5A). Accordingly, 8-CPT increased
NFAT nuclear translocation (supplementary Figure II). The
stimulating effect of 8-CPT on NFAT-Luc was significantly
blocked by a pharmacological inhibitor of calcineurin, cyclo-
sporine A (CsA) or transfection of a dominant negative form
of Epac (Epac1 to 148)21 (Figure 5A).
Recombinant EpacWT also increased NFAT transcriptional
activity which was blocked by CsA or an adenovirus bearing
a selective peptide inhibitor of calcineurin named VIVIT
(Ad.VIVIT)22 (Figure 5B and 5C). Consistent with these
findings, cardiac myocytes infected with Ad.EpacWT and
treated or not with 8-CPT (Figure 5D), or Ad.Epac-cAMP
(data not shown) had an increased content of mRNA encod-
ing the modulatory calcineurin-interacting protein 1
(MCIP1), a mediator of calcineurin signaling during cardiac
hypertrophy.23 Furthermore, coinfection with Ad.VIVIT and
Ad.EpacWT reduced the enhancement of sarcomeric organiza-
tion and cell surface area induced by Ad.EpacWT (Figure 6A
and 6B). Altogether these data show that NFAT is a down-
stream component of Epac hypertrophic signaling pathway.
Involvement of Rac in Epac-Induced
NFAT-Dependent Cardiomyocyte Hypertrophy
Because Rac was found to be a downstream component of
Epac signaling pathway (Figure 1), we next examined the
involvement of Rac in Epac-induced NFAT transcriptional
activity. Ad.RacS17N completely inhibited Epac-induced
NFAT transcriptional activity (Figure 7A) whereas the
stimulating effect of RacG12V on NFAT-Luc was blocked by
CsA (Figure 7B). These data clearly indicate that Rac is
able to influence the calcineurin/NFAT signaling pathway.
The involvement of Rac in Epac signaling pathway con-
trolling cardiomyocyte hypertrophy was further supported
by the observation that RacS17N inhibited the stimulating
effect of endogenous Epac activation or EpacWT on ANF
expression (Figure 7C and supplementary Figure III).
Consistent with these findings, Ad.RacS17N inhibited Epac-
induced cytoskeletal reorganization (Figure 7D) and in-
crease in cell surface area (Figure 7E). Finally, as Rac has
been shown to induce the production of reactive oxygen
species (ROS),24 we analyzed the effect of EpacWT on
ANF-Luc in the presence of the antioxidant,
N-acetylcysteine (NAC). We found that NAC inhibited
Epac-induced ANF-Luc activity suggesting that oxidative
stress is increased by Epac (supplementary Figure IV).
Figure 4. Intracellular Ca2 is involved in Epac- dependent Rac activation. A, Effect of 8-CPT (105 mol/L) on spontaneous spiking
activity at 1.8103 mol/L external [Ca2]. Cardiomyocytes at day 1 or 2 after plating were loaded with the Ca2 indicator Fluo3-AM
and perfused with a control external Ringer solution. B to D, Effect of ionomycin, thapsigargin and BAPTA-AM on Rac activation. Ven-
tricular cardiomyocytes were treated at 2 days in vitro with either ionomycin (10-6 mol/L) (B) or thapsigargin (0.2106 mol/L) (C) for dif-
ferent times of incubation or PE (105 mol/L) for 15 minutes. D, Cells were pretreated with BAPTA-AM (1.5 105 mol/L) for 10 minutes
and then they were stimulated with 8-CPT (105 mol/L) for 15 minutes. The amount of Rac-GTP was determined by pull-down
experiments.
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Discussion
The present study shows for the first time that cAMP-
dependent activation of Epac induces cardiomyocyte hyper-
trophy. This is based on our observation that Epac activation
leads to morphological changes, cytoskeletal reorganization,
increases in protein synthesis, and induces expression of
cardiac hypertrophic markers. In addition, we found that Epac
activates a prohypertrophic signaling pathway which involves
calcineurin and its primary downstream effector, NFAT.
Epac-induced NFAT activation was dependent on Rac activ-
ity. Interestingly, overexpression of Epac was able to influ-
ence cardiomyocyte morphology without cAMP analogue
treatment indicating that the level of intracellular cAMP was
sufficient to activate the recombinant EpacWT protein. Similar
observations have been reported in other cellular systems
because transfection of EpacWT in HEK293 and COS cells has
been previously shown to influence cell signaling and mor-
phology at resting basal cAMP levels.21 Because Epac needs
micromolar concentration of cAMP to be activated,4 theses
findings suggest that this cAMP-GEF may be localized in
subcellular membrane fractions of cardiomyocytes where
intracellular cAMP concentration is high. Further experi-
ments are required to determine the precise localization of
Epac in cardiac myocytes and its association with proteins (ie,
phosphodiesterases) that regulate cAMP gradient formation.
In our study, we showed that the Epac-specific cAMP
analogue 8-CPT produces bursts of Ca2 transients in neona-
tal cardiac myocytes. Our findings are in line with recent
studies in pancreatic -cells and INS-1 insulin-secreting cells,
demonstrating a Epac-dependent mobilization of intracellular
Ca2 by the cAMP-elevating hormone glucagon-like peptide
1 and the implication of Epac in this effect.25 In these cells,
activation of endogenous Epac triggers Ca2-induced Ca2
release26 and it is suggested that a functional coupling exists
between Epac and the RyR in these cellular systems.27
Interestingly, the small GTPase Rap1 which is an effector of
Epac is suspected to play a role in cAMP-induced [Ca2]i
increase via SERCA3b in megakaryocytes.28,29 Therefore,
Figure 5. Activation of NFAT by Epac. A to C, Effect of Epac on NFAT transcriptional activity. A, Cardiomycoytes were transfected with
NFAT-Luc, Epac-1 to 148, or the empty vector (mock) as control and treated or not with 8-CPT (106 mol/L) or CsA (0.5106 mol/L).
B and C, Cardiomyocytes infected with Ad.GFP (control), Ad.EpacWT, or Ad.VIVIT were transfected with NFAT-Luc and treated as
described. Two days after transfection, Luc activity was assayed. D, Epac increases MCIP1 expression. Cardiac myocytes infected
with Ad.GFP (control) or Ad.EpacWT were treated or not with 8-CPT (106 mol/L) for 2 days. The ratio of MCIP1/GCB mRNA was deter-
mined by quantitative PCR. Values are expressed relative to the MCIP1/GCB ratio. Results were normalized to control for each experi-
ment, and were expressed as meansSEM of at least 3 independent experiments performed in triplicate (A to C) or duplicate (D).
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one could imagine in cardiac myocytes, that Epac might
interact with Ca2 release channels. Such hypothesis is
currently undergoing investigation.
We found that Epac induced Rac activation in primary
cardiomyocytes. This is in accordance with our recent find-
ings showing that Epac induces Rac activation in a cAMP-
dependent but PKA-independent manner in noncardiac cells
such as primary cortical neurons and CHO cells.11 Because
we found that Rac was activated by Ca2 on Epac stimulation,
it is reasonable to think that Rac might be regulated by a GEF,
which is sensitive to Ca2. Such a GEF has been reported for
small GTPases of the Ras family.30,31 Another molecular
target which could be involved in Ca2-dependent Rac
activation is the Rho GDP-dissociation inhibitor (RhoGDI).
RhoGDI retains Rac into the cytoplasm and must dissociate
to allow Rac to encounter its GEFs.32,33 Recently, Price et al34
have shown that Ca2 induces a disruption of the Rac-
RhoGDI complex leading to the translocation and activation
of Rac in PC3 cells. Thus, one could speculate that such a
mechanism might occur in cardiomyocytes and contribute to
Epac-induced Ca2-dependent Rac activation
We report for the first time to our knowledge that Epac is
implicated in the activation of NFAT in cardiac myocytes.
The ability of Epac to stimulate NFAT activity was signifi-
cantly inhibited by treatment with CsA and VIVIT, suggest-
ing that calcineurin activity is regulated by Epac. Accord-
ingly, we found that Epac upregulates the expression of
MCIP1, a well known modulator of calcineurin signaling that
possesses a series of NFAT binding sites in its gene promot-
er.23,35 In addition, Ad.VIVIT partially reversed Epac-
induced cardiomyocyte hypertrophy indicating that Epac is a
new regulator of the hypertrophic calcineurin/NFAT signal-
ing pathway. As the Ca2/calmodulin-dependent protein ki-
nase II (CaMKII) is well-known to play a key role in cardiac
hypertrophy,36 it would be interesting to test the potential
involvement of this signaling pathway in Epac-induced car-
diac hypertrophy. In addition, Epac might be an important
mediator of oxidative stress because an antioxidant blocked
its effect on ANF-Luc. In accordance with this observation,
Rac activation is thought to be an important mediator of ROS
production induced by adrenoreceptor stimulation.37 Further-
more, G(12/13)-mediated ROS production is essential for an-
giotensin II-induced NFAT transcriptional activation.24
An important finding of the present study is that the effect
of Epac on NFAT activation was inhibited by RacS17N, a
negative dominant form of Rac. Inversely, Rac under its
activated form increased NFAT activity and this effect was
blocked by CsA. In line with these data, we found that RacS17N
inhibited Epac-induced ANF transcriptional activity and cell
growth. Altogether these results indicate that Rac is involved
in the regulation of the hypertrophic calcineurin/NFAT sig-
naling pathway initiated by Epac in cardiomyocytes. In
contrast to our findings, a previous study has shown that Ras
but not Rho GTPases regulates NFAT activity in cardiac
cells.38 The reasons for these discrepancies are still unclear.
However, the stimulating effect of Rac on NFAT activity is
supported by previous reports showing that humoral factors
induce Rac-dependent NFAT activation in various cellular
systems including immune and cardiac cells.24,39,40 In addi-
tion, RacG12V has been shown to upregulate ANF expression
in rat primary cardiac myocytes.14
Besides Epac, sustained activation of other cAMP effectors
have been shown to be deleterious for cardiac cells. For
instance, constitutive activation of PKA in the hearts of
transgenic mice leads to cardiomyocyte hypertrophy and a
progressive decline in cardiac function.41 In a similar manner,
increasing 1-adrenergic receptor (1-AR) signaling cascade
or Gs protein levels induces, through intracellular Ca2
elevation, a progressive development of cardiac hypertrophy
and heart failure.42,43 But although our data and the these
observations point to a negative role of persistent activity of
Figure 6. Ad.VIVIT inhibits Epac-induced cardiomyocyte hyper-
trophy. A, Fluorescent microscopic analyses of the effects of
Epac on sarcomeric organization. Morphology of representative
myocytes 48 hours after infection with Ad.GFP (control),
Ad.VIVIT, Ad.EpacWT, or Ad.EpacWT and Ad.VIVIT is shown. B,
Photographic images of cardiac myocytes infected as above
were digitized. Areas (106 m2) of around 50 individualized cells
per condition from 3 independent experiments were determined
by computer-assisted planimetry. Values show the
meansSEM. *P0.05, **P0.01, and ***P0.001 compared
with control or vs indicated values.
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cAMP/Epac/PKA, any elevation of cAMP does not automat-
ically cause deleterious effects. For instance, transgenic mice
overexpressing 2-AR in the heart,44 Adenyl cyclase type 6
(AC6)45 or AC846 do not show early signs of hypertrophy or
heart failure. Clearly, these data show that the same second
messenger conveys different information and cAMP com-
partmentation is a key actor and determines the quality of the
response. As a next step, it therefore will be crucial to
determine not only the spatial localization of Epac and its
possible interaction with cAMP-PDE but also the neurohor-
monal factors which are involved in the regulation of its
activity.
Thus, we propose a new cAMP signaling pathway in which
activation of Epac leads to an increase in [Ca2]i, which then
activates calcineurin and Rac. The latter controls NFAT
activation. This signaling cascade activates hypertrophic gene
expression and induces the morphological aspects of cardiac
myocyte hypertrophy. Our results thus open new insights into
the signaling pathways by which cAMP may mediate its
biological effects in cardiomyocytes.
Figure 7. Involvement of Rac in Epac-induced NFAT-dependent cardiomyocyte hypertrophy. A to C, Cardiomyocytes infected with
Ad.GFP (control), Ad.RacS17N, Ad.EpacWT, or Ad.EpacWT, and Ad.RacS17N were transfected with either NFAT-Luc or ANF-Luc. Two days
after, Luc activity was determined. Values are meansSEM of at least 3 separate experiments performed in triplicate. D and E,
Ad.RacS17N reverses Epac-induced cardiomyocyte hypertrophy. D, Photographic images of cells infected for 2 days with Ad.GFP (con-
trol), Ad.EpacWT, Ad.RacS17N, or Ad.EpacWT, and Ad.RacS17N were digitized. E, The areas (106 m2) of 50 individualized cells per condition
from 3 independent experiments were determined by computer-assisted planimetry. Values show the meansSEM. *P0.05, **P0.01,
and ***P0.001 vs control cells or indicated values.
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